Table Info

Table 1.

Primary sequences of genes

Common name	Primary couples (5’–3’)	Product size (bp)
IP₃RI	Forward: TGACGAGAACCTGCCCTAT Reverse: TCCTTTCGCCATCTTGCT	304
IP₃R2	Forward: GCAATCGTGTCTGTTCCA Reverse: TCTTCAAGTCTCAGCATCG	332
IP₃R3	Forward: GCCTACTATGAGAACCACACG Reverse: CAGAAGAGCAATGAGATGAGAG	389
RYRI	Forward: TGACTACCATCAGCACGACA Reverse: ACGAAGACGGCAGGAAATA	297
RYR2	Forward: AACAAGTACATGCCTGGTTTGC Reverse: TTGTTCTCATCAGGGAACAGGG	348
SERCAI	Forward: GTGATCCGCCAGCTAATG Reverse: CGAATGTCAGGTCCGTCT	361
SERCA2	Forward: CGCTACCTCATCTCGTCCA Reverse: TCGGGTATGGGGATTCAA	406
SERCA3	Forward: GATGGAGTGAACGACGCA Reverse: CCAGGTATCGGAAGAAGAG	409
NCX1	Forward: GTCGCACTTGGAACATCA Reverse: CCAGGGAGGAGAAGAAAA	373
NCX2	Forward: CGGTGGATAAACTCATCAAGAA Reverse: CAGGGCAACGAAGACAACA	359
NCX3	Forward: GAGATGGGAAAGCCAGTAT Reverse: ATGCCACGAAAACAACAG	430
PMCA1	Forward: GAGATGGGAAAGCCAGTAT Reverse: ATGCCACGAAAACAACAG	418
PMCA2	Forward: GAGATGGGAAAGCCAGTAT Reverse: ATGCCACGAAAACAACAG	214
PMCA3	Forward: TGGTCCTCTACTTTGTGATTG Reverse: TGGTGGTATAGGCACTGTTG	417
PMCA4	Forward: CTGTGCGTAATGAAGTGC Reverse: AGTCCCGGTAAGCTATG	279

Declarations

Acknowledgements

We would like to thank Mr. Ali Öztürk for them support in this study.

Author contributions

LY, BK, and DE contributed conception and design of the study; LY, DE, and FA organized the database; LY performed the statistical analysis; BK wrote the first draft of the manuscript; and LY, BK and DE wrote sections of the manuscript. All authors contributed to manuscript revision, read and approved the submitted version.

Conflicts of interest

Regarding this study, the authors and/or family members have no scientific or medical committee membership or relationship with their members, counseling, expertise, employment status in any company, shareholding, and similar situations.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

This work was supported by Istanbul University Scientific Research Projects Coordination Unit. Project number: TSA-2017-24579. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright

References

Büsselberg D, Florea AM. Targeting intracellular calcium signaling ([Ca²⁺]_i) to overcome acquired multidrug resistance of cancer cells: a mini-overview. Cancers (Basel). 2017;9:48. [DOI]

Kazan HH, Urfali-Mamatoglu C, Gunduz U. Iron metabolism and drug resistance in cancer. Biometals. 2017:30;629–41. [DOI] [PubMed]

Xu L, Xie Q, Qi L, Wang C, Xu N, Liu W, et al. Bcl-2 overexpression reduces cisplatin cytotoxicity by decreasing ER-mitochondrial Ca²⁺ signaling in SKOV3 cells. Oncol Rep. 2018;39:985–92. [DOI] [PubMed] [PMC]

Kouba S, Ouldamer L, Garcia C, Fontaine D, Chantome A, Vandier C, et al. Lipid metabolism and calcium signaling in epithelial ovarian cancer. Cell Calcium. 2019;5:38–50. [DOI]

Cui C, Merritt R, Fu L, Pan Z. Targeting calcium signaling in cancer therapy. Acta Pharm Sin B. 2017;7:3–17. [DOI] [PubMed] [PMC]

Santulli G, Nakashima R, Yuan Q, Marks AR. Intracellular calcium release channels: an update. J Physiol. 2017;595:3041–51. [DOI] [PubMed] [PMC]

Lencesova L, Krizanova O. IP₃ receptors, stress and apoptosis. Gen Physiol Biophys. 2012;31:119–30. [DOI] [PubMed]

Hegedũs L, Garay T, Molnár E, Varga K, Bilecz Á, Török S, et al. The plasma membrane Ca²⁺ pump PMCA4b inhibits the migratory and metastatic activity of BRAF mutant melanoma cells. Int J Cancer. 2017;140:2758–70. [DOI] [PubMed]

Fodor J, Gombo-Toth A, Olah T, Zador E, Toht ZC, Ioannis I, et al. Alteration of sarcoplasmic reticulum Ca²⁺ ATPase expression in lower limb ischemia caused by atherosclerosis obliterans. Physiol Int. 2017;104:183–92. [DOI] [PubMed]

10.

Marques O, da Silva BM, Porto G, Lopes C. Iron homeostasis in breast cancer. Cancer Lett. 2014;347:1–14. [DOI] [PubMed]

11.

Kucukkaya B, Basoglu H, Erdag D, Akbas F, Susgun S, Yalcintepe L. Calcium homeostasis in cisplatin resistant epithelial ovarian cancer. Gen Physiol Biophys. 2019;38:353–63. [DOI] [PubMed]

12.

Prencipe M, Fitzpatrick P, Gorman S, Tosetto M, Klinger R, Furlong F, et al. Cellular senescence induced by aberrant MAD2 levels impacts on paclitaxel responsiveness in vitro. Br J Cancer. 2009;101:1900–8. [DOI] [PubMed] [PMC]

13.

Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C_T method. Nat Protoc. 2008;3:1101–8. [DOI] [PubMed]

14.

Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014;740:364–78. [DOI] [PubMed] [PMC]

15.

Dulhunty AF, Beard NA, Casarotto MG. Recent advances in understanding the ryanodine receptor calcium release channels and their role in calcium signaling. F1000Res. 2018;7:F1000 Faculty Rev-1851. [DOI] [PubMed] [PMC]

16.

Humeau J, Bravo-San Pedro JM, Vitale I, Nunez L, Villalobos C, Kroemer G, et al. Calcium signaling and cell cycle: progression or death. Cell Calcium. 2017;70:3–15. [DOI] [PubMed]

17.

Kahl CR, Means AR. Calcineurin regulates cyclin D1 accumulation in growth-stimulated fibroblasts. Mol Biol Cell. 2004;15:1833–42. [DOI] [PubMed] [PMC]

18.

Prevarskaya N, Ouadid-Ahidouch H, Skryma R, Shuba Y. Remodelling of Ca²⁺ transport in cancer: how it contributes to cancer hallmarks? Philos Trans R Soc Lond B Biol Sci. 2014;369:20130097. [DOI]

19.

Bouchard V, Demers MJ, Thibodeau S, Laquerre V, Fujita N, et al. Fak/Src signaling in human intestinal epithelial cell survival and anoikis: differentiation state-specific uncoupling with the PI3-K/Akt-1 and MEK/Erk pathways. J Cell Physiol. 2007;212:717–28. [DOI] [PubMed]

20.

Giannone G, Ronde P, Gaire M, Beaudouin J, Haiech J, Ellenberg J, et al. Calcium rises locally trigger focal adhesion disassembly and enhance residency of focal adhesion kinase at focal adhesions. J Biol Chem. 2004;279:28715–23. [DOI] [PubMed]

21.

Tai YL, Chen LC, Shen TL. Emerging roles of focal adhesion kinase in cancer. Biomed Res Int. 2015;2015:690690. [DOI] [PubMed] [PMC]

22.

Brini M, Carafoli E. Calcium pumps in health and disease. Physiol Rev. 2009;89:1341–78. [DOI] [PubMed]

23.

Foskett JK, White C, Cheung KH, Mak DO. Inositol trisphosphate receptor Ca²⁺ release channels. Physiol Rev. 2007;87:593–658. [DOI] [PubMed] [PMC]

24.

Miyakawa T, Maeda A, Yamazawa T, Hirose K, Kurosaki T, Iino M. Encoding of Ca²⁺ signals by differential expression of IP₃ receptor subtypes. EMBO J. 1999;18:1303–8. [DOI] [PubMed] [PMC]

25.

Bustos G, Cruz P, Lovy A, Cárdenas C. Endoplasmic reticulum-mitochondria calcium communication and the regulation of mitochondrial metabolism in cancer: a novel potential target. Front Oncol. 2017;8:199. [DOI]

26.

Kang HY, Kim NS, Lee CO, Lee JY, Kang WH. Expression and function of ryanodine receptors in human melanocytes. J Cell Physiol. 2000;185:200–6. [DOI] [PubMed]

27.

Lanner JT, Georgiou DK, Joshi AD, Hamilton SL. Ryanodine receptors: structure, expression, molecular details, and function in calcium release. Cold Spring Harb Perspect Biol. 2010;2:a003996. [DOI] [PubMed] [PMC]

28.

Hamilton SL, Serysheva II. Ryanodine receptor structure: progress and challenges. J Biol Chem. 2009;284:4047–51. [DOI] [PubMed] [PMC]

29.

Endo Y, Uzawa K, Mochida Y, Shiiba M, Bukawa H, Yokoe H, et al. Sarcoendoplasmic reticulum Ca²⁺ ATPase type 2 downregulated in human oral squamous cell carcinoma. Int J Cancer. 2004;110:225–31. [DOI] [PubMed]

30.

Pacifico F, Ulianich L, De Micheli S, Treglia S, Leonardi A, Vito P, et al. The expression of the sarco/ endoplasmic reticulum Ca²⁺-ATPases in thyroid and its down-regulation following neoplastic transformation. J Mol Endocrinol. 2003;30:399–409. [DOI] [PubMed]

31.

Bergner A, Kellner J, Tufman A, Huber RM. Endoplasmic reticulum Ca²⁺-homeostasis is altered in Small and non-small Cell Lung Cancer cell lines. J Exp Clinical Cancer Res. 2009;28:25. [DOI] [PubMed] [PMC]

32.

Chung FY, Lin SR, Lu CY, Yeh CS, Chen FM, Huang TJ, et al. Sarco/endoplasmic reticulum calcium-ATPase 2 expression as a tumor marker in colorectal cancer. Am J Surg Pathol. 2006;30:969–74. [DOI] [PubMed]

33.

Arbabian A, Brouland JP, Gelebart P, Kovàcs T, Bobe R, Enouf J, et al. Endoplasmic reticulum calcium pumps and cancer. BioFactors. 2011;37:139–49. [DOI] [PubMed]

34.

Li W, Ouyang Z, Zhang Q, Wang L, Shen Y, Wu X, et al. SBF-1 exerts strong anticervical cancer effect through inducing endoplasmic reticulum stress-associated cell death via targeting sarco/endoplasmic reticulum Ca²⁺-ATPase 2. Cell Death Dis. 2014;5:e1581. [DOI] [PubMed] [PMC]

35.

Pelzl L, Hosseinzadeh Z, Alzoubi K, Al-Maghout T, Schmidt S, Stournaras C, et al. Impact of Na⁺/Ca²⁺ exchangers on therapy resistance of ovary carcinoma cells. Cell Physiol Biochem. 2015;37:1857–68. [DOI] [PubMed]

36.

Pelzl L, Hosseinzadeh Z, Al-Maghout T, Singh Y, Sahu I, Bissinger R, et al. Role of Na⁺/Ca²⁺ exchangers in therapy resistance of medulloblastoma cells. Cell Physiol Biochem. 2017;42:1240–51. [DOI] [PubMed]

37.

Papp B, Brouland JP. Altered endoplasmic reticulum calcium pump expression during breast tumorigenesis. Breast Cancer (Auckl). 2011;5:163–74. [DOI] [PubMed] [PMC]

38.

Aung CS, Ye W, Plowman G, Peters AA, Monteith GR, Roberts-Thomson SJ. Plasma membrane calcium ATPase 4 and the remodeling of calcium homeostasis in human colon cancer cells. Carcinogenesis. 2009;30:1962–9. [DOI] [PubMed]

39.

Ribiczey P, Tordai A, Andrikovics H, Filoteo AG, Penniston JT, Enouf J, et al. Isoform-specific up-regulation of plasma membrane Ca²⁺ ATPase expression during colon and gastric cancer cell differentiation. Cell Calcium. 2007;42:590–605. [DOI] [PubMed] [PMC]

40.

Curry MC, Luk NA, Kenny PA, Roberts-Thomson SJ, Monteith GR. Distinct regulation of cytoplasmic calcium signals and cell death pathways by different plasma membrane calcium ATPase isoforms in MDA-MB-231 breast cancer cells. J Biol Chem. 2012;287:28598–608. [DOI] [PubMed] [PMC]

41.

Varga K, Pászty K, Padányi R, Hegedűs L, Brouland JP, Papp B, et al. Histone deacetylase inhibitor- and PMA-induced upregulation of PMCA4b enhances Ca²⁺ clearance from MCF-7 breast cancer cells. Cell Calcium. 2014;55:78–92. [DOI] [PubMed]

42.

Rüschoff JH, Brandenburger T, Strehler EE, Filoteo AG, Heinmöller E, Aumüller G, et al. Plasma membrane calcium ATPase expression in human colon multistep carcinogenesis. Cancer Invest. 2012;30:251–7. [DOI] [PubMed]

43.

Barabas K, Faulk WP. Transferrin receptors associate with drug resistance in cancer cells. Biochem Biophys Res Commun. 1993;197:702–8. [DOI] [PubMed]

44.

Davies PS, Zhang AS, Anderson EL, Roy CN, Lampson MA, McGraw TE, et al. Evidence for the interaction of the hereditaryhaemochromatosis protein, HFE, with the transferrin receptorinendocyticcompartments. Biochem J. 2003;373:145–53. [DOI] [PubMed] [PMC]

45.

Necker LM. Regulation of transferrin receptor expression and control of cell growth. Pathobiology. 1991;59:11–8. [DOI] [PubMed]

46.

Cornwell MM, Pastan I, Gottesman MM. Certain calcium channel blockers bind specifically to multidrug-resistant human KB carcinoma membrane vesicles and inhibit drug binding to P-glycoprotein. J Biol Chem. 1987;262:2166–70. [PubMed]